 The purpose of this study is to determine whether left ventricular function improves more rapidly with deferoxamine DFO and deferiprone L1 combination therapy than with DFO monotherapy in patients with thalassemia and decreased ejection fractions. Secondary aims include evaluating changes in myocardial iron burden using T2 and estimating the relative incidence and severity of chelator-induced toxicity. 